These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 1623766)

  • 21. Industry-sponsored grand rounds and prescribing behavior.
    Dieperink ME; Drogemuller L
    JAMA; 2001 Mar; 285(11):1443-4. PubMed ID: 11255418
    [No Abstract]   [Full Text] [Related]  

  • 22. Interactions between physicians and the pharmaceutical industry generally and sales representatives specifically and their association with physicians' attitudes and prescribing habits: a systematic review.
    Fickweiler F; Fickweiler W; Urbach E
    BMJ Open; 2017 Sep; 7(9):e016408. PubMed ID: 28963287
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study.
    Fleischman W; Agrawal S; King M; Venkatesh AK; Krumholz HM; McKee D; Brown D; Ross JS
    BMJ; 2016 Aug; 354():i4189. PubMed ID: 27540015
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of interventions designed to increase market share and prescribing of fexofenadine at HMOs.
    Benedetto SR; Sloan AS; Duncan BS
    Am J Health Syst Pharm; 2000 Oct; 57(19):1778-85. PubMed ID: 11030030
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of Pharmaceutical Industry Marketing of Opioid Products to Physicians With Subsequent Opioid Prescribing.
    Hadland SE; Cerdá M; Li Y; Krieger MS; Marshall BDL
    JAMA Intern Med; 2018 Jun; 178(6):861-863. PubMed ID: 29799955
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Attitudes and behaviour of general practitioners and their prescribing costs: a national cross sectional survey.
    Watkins C; Harvey I; Carthy P; Moore L; Robinson E; Brawn R
    Qual Saf Health Care; 2003 Feb; 12(1):29-34. PubMed ID: 12571342
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of marketing in pharmaceutical research and development.
    Calfee JE
    Pharmacoeconomics; 2002; 20 Suppl 3():77-85. PubMed ID: 12457428
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Medication prescribing advice and drug utilization: a review from the United Kingdom.
    Law J; Thompson A
    Pharm Pract Manag Q; 1996 Jan; 15(4):27-35. PubMed ID: 10153842
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drivers of the opioid crisis: An appraisal of financial conflicts of interest in clinical practice guideline panels at the peak of opioid prescribing.
    Spithoff S; Leece P; Sullivan F; Persaud N; Belesiotis P; Steiner L
    PLoS One; 2020; 15(1):e0227045. PubMed ID: 31978076
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of Industry Payments on Prescribing Patterns for Tumor Necrosis Factor Inhibitors Among Medicare Beneficiaries.
    Singh P; Forman H; Adamson AS; Mostaghimi A; Ogdie AR; Oganisian A; Barbieri JS
    J Gen Intern Med; 2019 Feb; 34(2):176-178. PubMed ID: 30324292
    [No Abstract]   [Full Text] [Related]  

  • 31. [Editorial: Hebebrand, J., Blanz, B., Herpertz-Dahlmann, B. & Lehmkuhl, G. 2012. Increase in the abundance of medical treatments, ethical principles and conflicts of interest in cooperation with the pharmaceutical industry].
    Frank R
    Z Kinder Jugendpsychiatr Psychother; 2013 Mar; 41(2):145-9. PubMed ID: 23425616
    [No Abstract]   [Full Text] [Related]  

  • 32. Doctors who take company cash are more likely to prescribe brand name drugs, analysis finds.
    McCarthy M
    BMJ; 2016 Mar; 352():i1645. PubMed ID: 27000964
    [No Abstract]   [Full Text] [Related]  

  • 33. Improving the appropriateness of physician prescribing.
    Lexchin J
    Int J Health Serv; 1998; 28(2):253-67. PubMed ID: 9595343
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug company sponsored symposia fulfil an important educational role.
    Collins IS
    Med J Aust; 2006 Dec 4-18; 185(11-12):673; author reply 674-5. PubMed ID: 17181523
    [No Abstract]   [Full Text] [Related]  

  • 35. Prescribing and drug costs in the province of Ontario.
    Lexchin J
    Int J Health Serv; 1992; 22(3):471-87. PubMed ID: 1644510
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Leveraging drug-utilization and external benchmarking data to drive change in prescribing behaviors.
    O'Neal BC; Couldry RJ; Wilkinson ST; Cannella CA; Williams CB; Scott LA; Simpson SQ
    Am J Health Syst Pharm; 2012 Nov; 69(21):1916-22. PubMed ID: 23111677
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pricing of prescription drugs and its impact on physicians' choice behavior.
    Miao-Sheng C; Yu-Ti S
    Health Care Manag Sci; 2008 Sep; 11(3):288-95. PubMed ID: 18826006
    [TBL] [Abstract][Full Text] [Related]  

  • 38. When is it cost-effective to change the behavior of health professionals?
    Mason J; Freemantle N; Nazareth I; Eccles M; Haines A; Drummond M
    JAMA; 2001 Dec; 286(23):2988-92. PubMed ID: 11743840
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Conflict of interest in continuing medical education - Studies on certified CME courses].
    Lenzen LM; Weidringer JW; Ollenschläger G
    Z Evid Fortbild Qual Gesundhwes; 2016; 110-111():60-8. PubMed ID: 26875037
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Measures to improve angiotensin receptor blocker prescribing efficiency in the UK: findings and implications.
    Martin A; Godman B; Miranda J; Tilstone J; Saleem N; Olsson E; Acosta A; Restrepo L; Bennie M
    J Comp Eff Res; 2014 Jan; 3(1):41-51. PubMed ID: 24345256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.